Daiichi Sankyo’s Datroway gets Japanese regulatory nod for first TROP-2 directed therapy for previously treated ...
Daiichi Sankyo, an innovative global healthcare company, announced that its Datroway (datopotamab deruxtecan) has been approved in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH …